Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Immunome (IMNM)
TipRanks (Thu, 10-Sep 10:40 AM ET)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 8-Sep 4:02 PM ET)
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire (Wed, 2-Sep 7:45 AM ET)
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire (Tue, 11-Aug 4:02 PM ET)
Business Wire (Mon, 20-Jul 7:30 AM ET)
Business Wire (Wed, 8-Jul 7:30 AM ET)
Business Wire (Thu, 11-Jun 7:30 AM ET)
Immunome's $400 Million Public Offering Draws Focus to Cancer Therapy Pipeline and Investor Demand
Market Chameleon (Wed, 17-Dec 2:55 AM ET)
Immunome to Reveal Pivotal Phase 3 Results for Varegacestat in Desmoid Tumors—What’s at Stake?
Market Chameleon (Mon, 15-Dec 5:28 AM ET)
Immunome’s Varegacestat Delivers Landmark Efficacy in Phase 3 RINGSIDE Trial for Desmoid Tumors
Market Chameleon (Mon, 15-Dec 2:30 AM ET)
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Immunome trades on the NASDAQ stock market under the symbol IMNM.
As of September 10, 2026, IMNM stock price declined to $24.97 with 674,091 million shares trading.
IMNM has a beta of 1.05, meaning it tends to be more sensitive to market movements. IMNM has a correlation of 0.06 to the broad based SPY ETF.
IMNM has a market cap of $2.84 billion. This is considered a Mid Cap stock.
Last quarter Immunome reported $0 in Revenue and -$.65 earnings per share. This fell short of revenue expectation by $-533,336 and missed earnings estimates by -$.14.
In the last 3 years, IMNM traded as high as $30.96 and as low as $5.15.
The top ETF exchange traded funds that IMNM belongs to (by Net Assets): XBI, VTI, VXF, IWO, VTWO.
IMNM has outperformed the market in the last year with a return of +171.1%, while the SPY ETF gained +17.7%. In the last 3 month period, IMNM beat the market returning +35.8%, while SPY returned +3.1%. However, in the most recent 2 weeks IMNM has underperformed the stock market by returning -13.1%, while SPY returned -1.1%.
IMNM support price is $25.24 and resistance is $27.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNM shares will trade within this expected range on the day.
